ZyVersa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts $20.7 million pre-tax loss for Q3 2025
ZyVersa Therapeutics reported a pre-tax loss of $20.7 million for the third quarter ended September 30, 2025, compared to a pre-tax loss of $2.4 million for the same period in 2024. The increase in losses was primarily due to an $18.6 million impairment of research and development, related to a decline in market capitalization and uncertainty around financing research milestones. Cash on hand as of September 30, 2025, was $0.5 million. ZyVersa raised approximately $2.1 million in the third quarter and $4.1 million year-to-date. The company is advancing its pipeline, including VAR 200 for kidney diseases and IC 100 for chronic inflammatory diseases, and is seeking additional financing to support ongoing operations and development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579105-en) on November 19, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。